These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12628833)

  • 21. Isolation and characterization of degradation impurities in epirubicin hydrochloride injection.
    Kumar D; Tomar RS; Deolia SK; Srivastava R; Mitra M; Tyagi S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):45-53. PubMed ID: 18539101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Sensitivity of laboratory examinations in the diagnosis of chronic inflammatory liver diseases].
    Gros H; Zwirner K
    Med Klin; 1968 Oct; 63(40):1577-9. PubMed ID: 4180933
    [No Abstract]   [Full Text] [Related]  

  • 23. Liver transplantation for sickle cell hepatopathy.
    Friedman LS
    Liver Transpl; 2007 Apr; 13(4):483-5. PubMed ID: 17394145
    [No Abstract]   [Full Text] [Related]  

  • 24. [Liver in active hyperthyreosis].
    Meng W; Lorenz G; Eggert H; Meng S; Hampel R; Baufeld W
    Z Gesamte Inn Med; 1973 Dec; 28(24):787-91. PubMed ID: 4130587
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect on hepatic function of hepatic artery infusion chemotherapy using epirubicin and mitoxantrone for advanced hepatocellular carcinoma].
    Murata T; Nasu R; Kimura H; Uokawa K; Nagata K; Akagi K; Tanaka Y
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1707-11. PubMed ID: 9757196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A study of hepatic dysfunction in dengue.
    Shukla V; Chandr A
    J Assoc Physicians India; 2013 Jul; 61(7):460-1. PubMed ID: 24772748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
    Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the effect of adjusting epirubicin doses for body surface area?
    Dobbs NA; Twelves CJ
    Br J Cancer; 1998 Sep; 78(5):662-6. PubMed ID: 9744507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiphasic testing for liver-related abnormalities in hemorrhoidal disease.
    Ganchrow MI; Bowman HE
    Surg Gynecol Obstet; 1971 Mar; 132(3):478-82. PubMed ID: 5546301
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Ikeda M; Okusaka T; Ueno H; Morizane C; Iwasa S; Hagihara A; Kojima Y
    Oncology; 2007; 72(3-4):188-93. PubMed ID: 18097170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.
    Zhang CX; Zhao WY; Liu L; Ju RJ; Mu LM; Zhao Y; Zeng F; Xie HJ; Yan Y; Lu WL
    Oncotarget; 2015 Oct; 6(32):32681-700. PubMed ID: 26418720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diagnostic significance of serum conjugated bile acids].
    Schentke U; Jaross W; Trübsbach A; Renger F
    Z Gesamte Inn Med; 1972 Aug; 27(15):663-6. PubMed ID: 4641141
    [No Abstract]   [Full Text] [Related]  

  • 35. [Behavior of conjugated bile acids in the serum during liver diseases].
    Paumgartner G; Grabner G
    Acta Hepatosplenol; 1970; 17(5):344-53. PubMed ID: 5516233
    [No Abstract]   [Full Text] [Related]  

  • 36. [Reaction of the damaged liver in experimental choledochus occlusion].
    Vido J; Vido I; Moravec R
    Acta Hepatosplenol; 1966; 13(4):228-32. PubMed ID: 5987793
    [No Abstract]   [Full Text] [Related]  

  • 37. Hepatic diseases. Unsuspected before surgery.
    Wataneeyawech M; Kelly KA
    N Y State J Med; 1975 Jul; 75(8):1278-81. PubMed ID: 1055904
    [No Abstract]   [Full Text] [Related]  

  • 38. [Liver involvement in ulcerative colitis].
    Hornik J
    Z Arztl Fortbild (Jena); 1969 Apr; 63(7):383-5. PubMed ID: 5787544
    [No Abstract]   [Full Text] [Related]  

  • 39. [Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer].
    Nakao A; Sato S; Nakajima A; Nabeyama A; Okada Y; Sakagami K
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1831-4. PubMed ID: 7574817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Rupture of a liver cell carcinoma after chemoembolization].
    Schnarkowski P; Klüppelberg U; Lienemann A; Reiser MF
    Rofo; 1996 Apr; 164(4):341-3. PubMed ID: 8645870
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.